Haematologic Technologies

HTI is a leading provider of coagulation reagents for research, IVD and point-of-care device use, and analytical services, supporting the research, development, and commercialization of large-molecule biotherapeutics from inception through to market launch and beyond. HTI has deep expertise in protein biochemistry, including the characterization of plasma proteins and other large molecules, and supports discovery through commercial release with specialized assays for immunogenicity testing (anti-drug antibody detection), host cell protein mitigation, stability and release testing, thrombin generation assays, hemostasis risk assessment, and various other specialized assays tailored for biotherapeutics. The company’s biopharmaceutical services are performed in fully FDA-compliant GMP facilities.With over 30 years of expertise in plasma proteins, hemostasis, and coagulation, HTI is also a global leader in clotting research reagents (plasma proteins and antibodies), custom-formulated IVD/POC device reagents, and custom blood collection tubes.